MedTrace Logo

Assess Fibrin in Brains With AD/ADRD

NCT05336695 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-30

No results posted yet for this study

Summary

The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

Conditions

  • Alzheimer Disease
  • Dementia of Alzheimer Type

Interventions

DIAGNOSTIC_TEST

PET/MR Imaging

PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol

DRUG

64Cu-FBP8

Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Ciprian Catana, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-29
Primary Completion
2026-09-28
Completion
2026-09-28
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05336695 on ClinicalTrials.gov